WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has partnered with a global ingredient manufacturer to develop, scale, and commercialize a high-value ingredient from its internal portfolio. The collaboration includes R&D payments of up to $1.3 million and a 15-year tiered profit share arrangement. The 12-month research program targets a $1 billion global market segment currently dominated by chemically synthesized products. Willow aims to develop a high-purity, sustainable, bio-identical natural ingredient expected to be more cost-effective than chemical alternatives. The partner will handle regulatory compliance, manufacturing, and marketing responsibilities.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) ha collaborato con un produttore globale di ingredienti per sviluppare, scalare e commercializzare un ingrediente di alto valore dal proprio portafoglio interno. La collaborazione include pagamenti per R&S fino a 1,3 milioni di dollari e un accordo di condivisione dei profitti a livelli per 15 anni. Il programma di ricerca di 12 mesi mira a un segmento di mercato globale da 1 miliardo di dollari attualmente dominato da prodotti sintetizzati chimicamente. Willow punta a sviluppare un ingrediente naturale bio-identico ad alta purezza e sostenibile, previsto essere più conveniente rispetto alle alternative chimiche. Il partner si occuperà della conformità normativa, della produzione e delle responsabilità di marketing.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) se ha asociado con un fabricante de ingredientes global para desarrollar, escalar y comercializar un ingrediente de alto valor de su cartera interna. La colaboración incluye pagos de I+D de hasta 1,3 millones de dólares y un acuerdo de participación en las ganancias escalonado a 15 años. El programa de investigación de 12 meses tiene como objetivo un segmento de mercado global de 1 mil millones de dólares actualmente dominado por productos sintetizados químicamente. Willow tiene como objetivo desarrollar un ingrediente natural bioidéntico de alta pureza y sostenible que se espera que sea más rentable que las alternativas químicas. El socio se encargará del cumplimiento normativo, la fabricación y las responsabilidades de marketing.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF)가 전 세계 성분 제조업체와 협력하여 내부 포트폴리오에서 고부가가치 성분을 개발, 확대 및 상용화합니다. 이번 협력은 130만 달러까지의 연구 개발 비용과 15년 간의 단계별 이익 공유 협정을 포함합니다. 12개월 연구 프로그램의 목표는 현재 화학적으로 합成된 제품이 지배하고 있는 10억 달러의 글로벌 시장 부문입니다. Willow는 화학 대안보다 경제성이 더 높을 것으로 예상되는 고순도의 지속 가능하고 생체 동일한 자연 성분 개발을 목표로 합니다. 파트너는 규제 준수, 제조 및 마케팅 책임을 맡게 됩니다.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) a noué un partenariat avec un fabricant d'ingrédients mondial pour développer, étendre et commercialiser un ingrédient de grande valeur issu de son portefeuille interne. La collaboration inclut des paiements R&D allant jusqu'à 1,3 million de dollars et un accord de partage des profits échelonné sur 15 ans. Le programme de recherche de 12 mois vise un segment de marché mondial d'un milliard de dollars actuellement dominé par des produits synthétisés chimiquement. Willow vise à développer un ingrédient naturel de haute pureté, durable et bio-identique qui devrait être plus économique que les alternatives chimiques. Le partenaire s'occupera de la conformité réglementaire, de la fabrication et des responsabilités marketing.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) hat sich mit einem globalen Inhaltsstoffhersteller zusammengetan, um einen wertvollen Inhaltsstoff aus seinem internen Portfolio zu entwickeln, zu skalieren und zu vermarkten. Die Zusammenarbeit umfasst F&E-Zahlungen von bis zu 1,3 Millionen US-Dollar sowie eine 15-jährige, gestaffelte Gewinnbeteiligung. Das 12-monatige Forschungsprogramm zielt auf ein globales Marktsegment von 1 Milliarde US-Dollar, das derzeit von chemisch synthetisierten Produkten dominiert wird. Willow strebt die Entwicklung eines hochreinen, nachhaltigen, bioidentischen Naturinhaltsstoffs an, der voraussichtlich kosteneffektiver ist als chemische Alternativen. Der Partner wird die Verantwortung für die Einhaltung der Vorschriften, die Herstellung und den Vertrieb übernehmen.
- Potential R&D payments of up to $1.3 million
- 15-year tiered profit-sharing agreement
- Target market size of $1 billion
- Partner assumes costs for regulatory, manufacturing, and marketing
- Product expected to be lower cost than current chemical alternatives
- 12-month development timeline before potential commercialization
- Success-dependent payments tied to performance targets
Through this partnership, Willow expects to receive payments for research and development ("R&D") followed by a tiered profit share for 15 years after launch, if successful. The research program is expected to take 12 months to complete, with near-term payments for R&D to Willow of up to
"We are pleased to partner this ingredient that started as an internal program, with a global partner with commercial-scale manufacturing expertise and market access", said Dr. Chris Savile, Willow's President and Chief Executive Officer. "This partnership further validates our ability to select and develop products within large existing markets that can be improved with biomanufacturing, execute on the required science, and secure the appropriate commercialization partner."
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.
FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc.
Forward-Looking Statements
This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans, platforms, operations and expansion, and, more particularly, statements concerning: the new partnership agreement, including the ability to successfully, complete and transition the R&D program to commercial revenue; and the business plan of the Company, generally. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the partnerships with the new partner; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results biotechnology industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; competition from other industry participants; adverse
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Certain information contained herein has been obtained from published sources prepared by independent industry analysts and third-party sources (including industry publications, surveys and forecasts). While such information is believed to be reliable for the purposes used herein, Willow does not assume any responsibility for the accuracy of such information. The sources cited in this news release have not consented to the inclusion of any data from their reports, nor has Willow sought their consent.
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-new-partnership-with-a-global-ingredient-manufacturer-to-advance-development-of-a-high-value-ingredient-from-its-portfolio-302298543.html
SOURCE Willow Biosciences Inc.
FAQ
What is the potential market size for Willow Biosciences' (CANSF) new ingredient partnership?
How much R&D payment could Willow Biosciences (CANSF) receive from the new partnership?
What is the duration of the profit-sharing agreement in Willow Biosciences' (CANSF) new partnership?
How long is the research program expected to take for Willow Biosciences' (CANSF) new ingredient?
